The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Protasova A.E.

The Federal Almazov North-West Medical Research Centre, Sainkt-Petersburg, Russia,197341

Vandeeva E.N.

The Federal Almazov North-West Medical Research Centre, Sainkt-Petersburg, Russia,197341

Kuzmina N.S.

The Federal Almazov North-West Medical Research Centre, Sainkt-Petersburg, Russia,197341

Is endometriosis a benign disease? Modern controversial aspects of endometriosis-associated ovarian tumors

Authors:

Protasova A.E., Vandeeva E.N., Kuzmina N.S.

More about the authors

Journal: Russian Journal of Human Reproduction. 2016;22(5): 98‑109

DOI: 10.17116/repro201622598-109

Views: 15347

Downloaded: 122

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Protasova AE, Vandeeva EN, Kuzmina NS. Is endometriosis a benign disease? Modern controversial aspects of endometriosis-associated ovarian tumors. Russian Journal of Human Reproduction. 2016;22(5):98‑109. (In Russ.)
https://doi.org/10.17116/repro201622598-109

 
МСФ на ЯМ
Close metadata
Recommended articles:
Immu­nological aspe­cts of endo­metriosis: pathophysiological mechanisms, diagnosis, autoimmunity, targeted therapy and modu­lation. Russian Journal of Human Reproduction. 2024;(2):15-31
Analysis of the effe­ctiveness of various methods of mana­ging patients with endo­metriosis and justification for long-term personalized anti-relapse therapy with dydrogesterone as part of their combination treatment stra­tegy. Russian Journal of Human Reproduction. 2024;(2):102-111
Infi­ltrating Endo­metriosis of the Distal Part of Round Uterine Liga­ment and It’s Asso­ciation with Nuck’s Dive­rticulum (Literature Review and Case Report). Russian Journal of Human Reproduction. 2024;(2):112-121
Endo­metriosis and geni­tal malformations in children and adolescents. What do they have in common?. Russian Journal of Human Reproduction. 2024;(3):14-22
Benign breast diseases in the focus of proliferative pathology of the reproductive system. Russian Journal of Human Reproduction. 2024;(3):33-42
Pathogenetic aspe­cts of chro­nic pelvic pain in endo­metriosis: diagnostic prospects (literature review). Russian Journal of Human Reproduction. 2024;(4):112-120
The role of systemic and local immu­nity in the pathogenesis of endo­metriosis of varying degrees of prevalence of the process: a modern view. Russian Journal of Human Reproduction. 2024;(5):6-14
The role of ferroptosis in reproduction. A modern view of the problem. Russian Journal of Human Reproduction. 2024;(5):35-45
The influence of endo­metriosis on the quality of life and reproductive function of modern woman. Russian Journal of Human Reproduction. 2024;(5):101-107
Quality of life and psychosomatic status of women of reproductive age with adenomyosis. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):83-89

Endometriosis is a benign disease, occupying the third place in the structure of gynecological morbidity, increasing the risk of development of a number of endometriosisassociated malignant tumors. Search the community of pathogenesis of diseases, optimization of treatment, the implementation of the reproductive function, reduce risk of development of endometriosisassociated ovarian tumors.

Keywords:

endometriosis
endometriosisassociated tumors
genetic mutation
dienoguest

Authors:

Protasova A.E.

The Federal Almazov North-West Medical Research Centre, Sainkt-Petersburg, Russia,197341

Vandeeva E.N.

The Federal Almazov North-West Medical Research Centre, Sainkt-Petersburg, Russia,197341

Kuzmina N.S.

The Federal Almazov North-West Medical Research Centre, Sainkt-Petersburg, Russia,197341

List of references:

  1. Adamyan LV, Andreeva EN, Apolikhina IA, Bejenari VF, Gevorgian MA, Gus AI, Demidov VN, Kalinina EA, Levakov SA, Marchenko LA, Popov AA, Sonova MM, Hashokueva AZ, Chernuha GE, Yarotskaya E.L. Endometriosis: Diagnosis , treatment and rehabilitation . Federal clinical rekomndation for the management of patients. Federal clinical rekomndtion i for the management of patients. M. 2013. (In Russ.).
  2. Sonova MM, Adamyan LV, Jordania KI, Payanidi UG. Endometriosis and ovarian cancer . Is there a relationship ? Common pathogenic features of ovarian cancer and endometriosis. Oncogynecology. 2013;4:30-40. (In Russ.).
  3. Greene R, Stratton P, Cleary SD, Ballweg ML., Sinaii N. Diagnostic experience among 4,334 women reporting surgically diagnosed endometriosis. Fertil Steril. 2009;91:32-39. doi: 10.1016/j.fertnstert.2007.11.020
  4. Marsh EE, Laufer MR. Endometriosis in premenarcheal girls who do not have an associated obstructive anomaly. Fertil Steril. 2005;83(3):758-760. doi: 10.1016/j.fertnstert.2004.08.025
  5. Ballweg ML. Big picture of endometriosis helps provide guidance on approach to teens: comparative historical data show endo starting younger, is more severe. J Pediatr Adolesc Gynecol. 2003;16 (3):21-26. doi: 10.1016/s1083-3188(03)00063-9
  6. Orlova SA, Balan VE, Lewkowicz EA. Current trends of drug treatment of endometriosis. Medical advice. Obstetrics and gynecology. 2015;2:28-32.
  7. Brosens I, Puttemans P, Benagiano G. Endometriosis: a life cycle approach? American Journal of Obstetrics & Gynecology. 2013;209(4):307-316. doi: 10.1016/j.ajog.2013.03.009
  8. Gasparov AS, Zhordania K I, Payanidi Yu G, Dubinskaya. E D. Oncological aspects of cystic ovarian structures. Bulletin of the Russian Academy of medical Sciences. 2013;68(8):9-13. (In Russ.). doi:10.15690/vramn.v68i8.716
  9. Heidemann LN, Hartwell D, Heidemann CH, Kirsten M, JochumsenK M. The relation between endometriosis and ovarian cancer — a review. Acta Obstet Gynecol Scand. 2014;93(1):20-31. doi: 10.1111/aogs.12255
  10. Kim HS, Kim TH, Chung HH, Song S. Risk and prognosis of ovarian cancer in women with endometriosis: a metaanalysis. Br J Cancer. 2014;110(7):1878-1890. doi: 10.1038/bjc.2014.29
  11. Merabishvili VM. Cancer statistics (traditional methods, new information technologies): a Guide for physicians. Second edition, supplemented. Part I. 2015; 223.
  12. Sourial S, Tempest N, Hapangama DH. Theories on the Pathogenesis of Endometriosis. International Journal of Reproductive Medicine. 2014;1-9. doi: 10.1155/2014/179515
  13. Farquhar C. Endometriosis. BMJ. 2007;334(7587):249-253. doi:10.1136/bmj.39073.736829.be
  14. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Leigh Pearce C. Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility. 2016;105(1):35-43. doi: 10.1016/j.fertnstert.2015.09.023
  15. Vodolazkaia A, Yesilyurt BT, Kyama CM, Bokor A, Schols D, Huskens D, Meuleman C, Peeraer K, Tomassetti C, Bossuyt X, Lambrechts D, D'Hooghe T, Fasset A. Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers. Fertility and Sterility. 2016;105(4):988-996. doi: 10.1016/j.fertnstert.2015.12.016
  16. Gorbunova VN, Imyanitov EN. Genetics and carcinogenesis. Toolkit for medical students. SPbGPMA. 2007;24. (In Russ.).
  17. Svenssen Munksgaard P, Blaakaer J. The association between endometriosis and ovarian cancer: A review of histological,genetic and molecular alterations. Fertility and Sterility. 2016;105(1):164-169. doi: 10.1016/j.ygyno.2011.10.001
  18. Torre L, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics, 2012. A Cancer Journal for Clinicians. 2015;65(2):87-108. doi: 10.3322/caac.2126
  19. Kodaman PH. Current strategies for endometriosis management. Obstet Gynecol Clin North Am. 2015;42(1):87-101. doi: 10.1016/j.ogc.2014.10.005
  20. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci Jan. 2009;100:9-16. doi: 10.1111/j.1349-7006.2008.01001.x
  21. Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T. Endometriosis-associated Malignancy. Geburtsh Frauenheilk. 2016;76(2):176-181. doi: 10.1055/s-0035-1558239
  22. Grandi G, Toss A, Cortesi L, Botticelli L, Volpe A, Cagnacci A. The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during. Reproductive Life. 2015;2015:1-10. doi:10.1155/2015/751571.
  23. Ovarian Cancer — Risk Factors and Prevention,аpproved by the Cancer. Net Editorial Board. 2015;04.
  24. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24(2):235-258. doi: 10.1016/s0889-8545(05)70302-8
  25. Tanase Y, Furukawa N, Kobayashi H, Matsumoto T. Malignant Transformation from Endometriosis to Atypical Endometriosis and Finally to Endometrioid Adenocarcinoma within 10 Years. Case Rep Oncol. 2013;6(3):480-484. doi: 10.1159/000355282
  26. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. American Society for Reproductive Medicine. 1997;67(5):817-821. doi: 10.1016/s0015-0282(97)81391-x
  27. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42(7):918-931. doi: 10.1016/j.humpath.2011.03.003
  28. Yang HP, Trabert B, Murphy MA, Sherman ME., SampsonJN,. BrintonLA, Hartge P, Hollenbeck A, Park Y, Wentzensen N.Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. International Journal of Cancer.2012;131(4):938-948. doi: 10.1002/ijc.26469
  29. Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110(3):336-344. doi: 10.1016/j.ygyno.2008.05.025
  30. Davis M, Rauh-Hain JA, Andrade C , Boruta DM, Schorge JO, Horowitz NS, May T, Marcela G. del Carmen MG. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014;132(3):760-766. doi: 10.1016/j.ygyno.2014.01.012
  31. Vetvicka В, Kralickova М. Current theories on endometriosis pathogenesis. Edorium J Mol Pathol. 2015;4(1):1-4. doi: 10.7243/2052-7896-4-1
  32. Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie. Region of Quebec. Canada. J Ovarian Res. 2010;3(1):2. doi: 10.1186/1757-2215-3-2
  33. Buis CC, van Leeuwen FE, Mooij T M, Burger CW. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod. 2013;28(12):3358-3369. doi: 10.1093/humrep/det340
  34. Melin A, Sparén P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Human Reproduction. 2007;22(11):3021-3026. doi: 10.1093/humrep/dem209
  35. Modugno F, Roberta B, Allen GO, Schildkrau ОT, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. American Journal of Obstetrics and Gynecology. 2004;191(3):733-740. doi: 10.1016/j.ajog.2004.03.035
  36. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, Schlesselman JJ. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11(2):111-117. doi: 10.1097/00001648-200003000-00006
  37. Olson JE,Cerhan JR, Janney CA, Anderson KE, Vachon CM, Sellers TA. Postmenopausal cancer risk after self-reported endometriosis diagnosis in the Iowa Women's Health Study. Cancer. 2002;94(5):1612-1618. doi: 10.1002/cncr.10370
  38. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk associated with varying causes of infertility. 2004;82(2):405-414. doi: 10.1016/j.fertnstert.2004.02.109
  39. Borgfeldt С, Andolf Е. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstetricia et Gynecologica Scandinavica. 2004;83(4):395-400. doi: 10.1111/j.0001-6349.2004.00305.x
  40. Stewart LM, Holman CD, Aboagye-Sarfo P, Finn С, Preen DB, Hartet R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013;128(2):260-264. doi: 10.1016/j.ygyno.2012.10.023 Actions
  41. Nezhat FR, Apostol R, Nezhat G, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. American Journal of Obstetrics and Gynecology. 2015;213(3):262-267. doi: 10.1016/j.ajog.2015.03.044
  42. Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552-1568. doi: 10.1093/humrep/det050
  43. DiVasta AD, Laufer MR. The use of gonadotropin releasing hormone analogues in adolescent and young patients with endometriosis. Current Opinion in Obstetrics & Gynecology. 2013;25(4):287-292. doi: 10.1097/gco.0b013e32836343eb
  44. Li-Chi Chen, Ju-Wei Hsu, Kai-Lin Huang, Ya-Mei Bai, Tung-Ping Su, Cheng-Ta Li, Albert C Yang, Wen-Han Chang, Tzeng-Ji Chen, Shih-Jen Tsai, Mu-Hong Chen Chenetal. Risk of developing major depression andanxiety disorders among women with endometriosis: A longitudinal follow-up study. Journal of Affective Disorders. 2016;190:282-285. doi: 10.1016/j.jad.2015.10.030
  45. Quaas AM, Weedin EA, Hansen KR. On-label and off-label drug use in the treatment of endometriosis. Fertility and Sterility. 2015;103(3):612-625. doi: 10.1016/j.fertnstert.2015.01.006
  46. Ярмолинская М.И., Денисова В.М. Современные подходы к назначению add-back-терапии больным генитальным эндометриозом. Эффективная фармакотерапия. Акушерство и гинекология. 2015;4(36).
  47. Agarwal SK, Daniels A, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV, Daniels JR. Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone. Biomed Res Int. 2015;2015:1-9. doi: 10.1155/2015/934164
  48. Hayashi A, Tanabe A, Kawabe S, Hayashi M, Yuguchi H, Yamashita Y, Okuda K, Ohmichi M. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res. 2012;5(1):31. doi: 10.1186/1757-2215-5-31
  49. Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs. 2015;20(2):331-346. doi: 10.1517/14728214.2015.1036739
  50. Katayama H, Katayama T, Uematsu K, Hiratsuka M, Kiyomura M, Shimizu Y, Sugita A, Ito M. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod. 2010;25(11):2851-2858. doi: 10.1093/humrep/deq241
  51. Masayuki Ichioka, Shizuka Mita, Yutaka Shimizu, Kazunori Imada, Tohru Kiyono, Yukiko Bono, Satoru Kyo. Dienogest, a synthetic progestin, down-regulates expression of CYP19A1 and inflammatory and neuroangiogenesis factors through progesterone receptor isoforms A and B in endometriotic cells. Journal of Steroid Biochemistry & Molecular Biology. 2015;147:103-110. doi: 10.1016/j.jsbmb.2014.12.008
  52. Nakamura M, Katsuki Y, Shibutani Y, Oikawa T.Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesi. Eur J Pharmacol. 1999;386(1):33-40. doi: 10.1016/s0014-2999(99)00765-7
  53. Köhler G, Faustman TA, Gerlinger C, Seitz С, Muecket AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. International Journal of Gynecology and Obstetrics. 2010;108(1):21-25. doi: 10.1016/j.ijgo.2009.08.020
  54. Mueck AO. What makes dienogest a unique progestogen for the treatment of endometriosis? Expert Review of Obstetrics & Gynecology Gynaecol Forum. 2011;6(1):5-15. doi: 10.1586/eog.10.71
  55. Scarfone G, Bergamini A, Noli S, Villa A, Cipriani S, Taccagni G,Vigano'P, Candiani M, Parazzini F, Mangiliet G. Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecol Oncol. 2014;133(3):480-484. doi: 10.1016/j.ygyno.2014.03.017
  56. Tamura R, Tsuneki I, Yanase Effectiveness of the cyclic administration of dienogest in a case of pathological disappearance of intestinal endometriosis. Int J Womens Health. 2013;5:421-424. doi: 10.2147/IJWH.S43567
  57. McCormack PL. Dienogest: a review of its use in the treatment of endometriosis. Drugs. 2010;70(16):2073-2088. doi:10.2165/11206320-000000000-00000
  58. McCormack PL. Dienogest: a review of its use in the treatment of endometriosis. Drugs. 2010;70(16):2073-2088. doi: 10.2165/11206320-000000000-00000
  59. Somigliana E, Vercellini P, Vigano P, Benaglia L, Busnelli A, Fedele L. Postoperative Medical Therapy After Surgical Treatment of Endometriosis: From Adjuvant Therapy to Tertiary Prevention. J Minim Invasive Gynecol. 2014;21(3):328-334. doi: 10.1016/j.jmig.2013.10.007
  60. Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and metaanalysis. Human Reproduction Update. 2010;17(1):55-67. doi: 10.1093/humupd/dmq030
  61. Ovarian Cancers: Evolving Paradigms in Research and Care. Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Washington (DC): National Academies Press (US). 2016. doi: 10.17226/21841
  62. Rizk B, Fischer AS, Lotfy HA, et al. Recurrence of endometriosis after hysterectomy. Facts, Views & Vision in ObGyn. 2014;6(4):219-227.
  63. Joan L, Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, Borowsky ME, Gibb RK.Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108-2120. doi: 10.1002/cncr.29321 doi :10.1093/humrep/det457
  64. Sopik V, Rosen B, Giannakeas V, Narod SA. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. Gynecologic Oncology. 2015;138(3):757-761. doi: 10.1016/j.ygyno.2015.06.019
  65. Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang Y-L, Lin В. Breastfeeding and ovarian cancer risk: A meta-analysis of epidemiologic studies. American Journal of Clinical Nutrition. 2013;98(4):1020-1031. doi: 10.3945/ajcn.113.062794
  66. Fortner RT, Ose J, Merritt M.A, et al. Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort. International Journal of Cancer. 2015;137(5):1196-1208. doi: 10.1002/ijc.29471
  67. Gates MA, Rosner BA, Hecht JL, Tworoger SS, et al. Risk factors for epithelial ovarian cancer by histologic subtype. American Journal of Epidemiology. 2009;171(1):45-53. doi: 10.1093/aje/kwp314
  68. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H,. Xiang Y, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, et al. Type I and II endometrial cancers: Have they different risk factors? Journal of Clinical Oncology. 2013;31(20):2607-2618. doi: 10.1200/jco.2012.48.2596

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.